Bayer sues Johnson & Johnson over prostate cancer drug claims [USA TODAY]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: USA TODAY
In a complaint filed in Manhattan federal court, Bayer said Johnson & Johnson is causing irreparable harm through a campaign begun this month for the drug Erleada that threatens to erode trust in the German company's drug Nubeqa. Bayer said Johnson & Johnson falsely claimed that patients treated with Erleada had a "51% reduction in risk of death" compared with Nubeqa patients, in testing that replicated a clinical trial and adhered to "rigorous" U.S. Food and Drug Administration standards. According to the complaint, the two groups of patients were not comparable because most Nubeqa patients in the comparison received their drug off-label, creating "selection bias" that makes claims of superiority unreliable, and Johnson & Johnson's study included five times more patients. Bayer also said the FDA does not sanction the retrospective, real-world analysis that Johnson & Johnson allegedly used as a substitute for traditional clinical trials. "By invoking FDA authority to lend unw
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? [Yahoo! Finance]Yahoo! Finance
- 2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash [Yahoo! Finance]Yahoo! Finance
- Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves [Yahoo! Finance]Yahoo! Finance
- AstraZeneca News On Cancer And Asthma Raises New Questions For Investors [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/27/26 - Form 144
- 2/23/26 - Form 4
- 2/20/26 - Form 144
- JNJ's page on the SEC website